Type 3 innate lymphoid cells maintain intestinal epithelial stem cells after tissue damage by Aparicio-Domingo, P. (Patricia) et al.
The Rockefeller University Press $30.00
J. Exp. Med. 2015 Vol. 212 No. 11 1783–1791
www.jem.org/cgi/doi/10.1084/jem.20150318
1783
Brief Definit ive Report
The intestinal epithelium combines efficient 
uptake of nutrients and water while providing a 
physical barrier between the intestinal micro-
biota and the body (Peterson and Artis, 2014). 
Damage sustained by intestinal epithelial cells 
(IECs) needs to be swiftly and efficiently re-
paired to prevent inappropriate immune re-
sponses to commensal bacteria. Intestinal damage 
is an early event in the development of both 
graft-versus-host disease (Reddy and Ferrara, 
2003) and alimentary mucositis (Sonis, 2004) 
and a driver of bacterial translocation and T cell 
activation in inflammatory bowel disease (Salim 
and Söderholm, 2011).
A major pathway involved in the intestinal 
epithelial response to damage is the activation of 
Stat3, which is expressed along the crypt–villus 
axis of the intestinal epithelium (Grivennikov 
et al., 2009; Heneghan et al., 2013). Phosphory-
lated Stat3 translocates to the nucleus and acti-
vates genes involved in proliferation, survival, 
and mucosal defense (Bollrath et al., 2009; 
Pickert et al., 2009; Ernst et al., 2014). Muta-
tions in STAT3 have been identified as suscep-
tibility factors for inflammatory bowel disease 
(Bollrath et al., 2009; Anderson et al., 2011; 
Demaria et al., 2012), and in mice, upon DSS-
induced colitis, epithelial Stat3 is required for 
mucosal wound healing (Pickert et al., 2009).
Intestinal regeneration depends on the con-
tinuous differentiation of epithelial cells from 
crypt-residing intestinal stem cells (ISCs; Potten 
et al., 1978; Günther et al., 2013; Ritsma et al., 
2014). Even though multiple intestinal progenitor 
CORRESPONDENCE  
Tom Cupedo:  
t.cupedo@erasmusmc.nl
Abbreviations used: IEC, 
intestinal epithelial cell; ILC3, 
type 3 innate lymphoid cell; 
ISC, intestinal stem cell;  
MTX, methotrexate; qPCR, 
quantitative PCR.
*P. Aparicio-Domingo and M. Romera-Hernandez contributed 
equally to this paper.
Type 3 innate lymphoid cells maintain intestinal 
epithelial stem cells after tissue damage
Patricia Aparicio-Domingo,1* Monica Romera-Hernandez,1* Julien J. Karrich,1 
Ferry Cornelissen,1 Natalie Papazian,1 Dicky J. Lindenbergh-Kortleve,2  
James A. Butler,3 Louis Boon,4 Mark C. Coles,3 Janneke N. Samsom,2  
and Tom Cupedo1
1Department of Hematology and 2Department of Pediatrics, Division of Gastroenterology and Nutrition, Erasmus University 
Medical Center, 3015 CN Rotterdam, Netherlands
3Centre for Immunology and Infection, Department of Biology and Hull York Medical School, University of York, York YO10 5DD, 
England, UK
4Bioceros, 3584 CM Utrecht, Netherlands
Disruption of the intestinal epithelial barrier allows bacterial translocation and predis-
poses to destructive inflammation. To ensure proper barrier composition, crypt-residing 
stem cells continuously proliferate and replenish all intestinal epithelial cells within days. 
As a consequence of this high mitotic activity, mucosal surfaces are frequently targeted 
by anticancer therapies, leading to dose-limiting side effects. The cellular mechanisms 
that control tissue protection and mucosal healing in response to intestinal damage 
remain poorly understood. Type 3 innate lymphoid cells (ILC3s) are regulators of homeo-
stasis and tissue responses to infection at mucosal surfaces. We now demonstrate that 
ILC3s are required for epithelial activation and proliferation in response to small intesti-
nal tissue damage induced by the chemotherapeutic agent methotrexate. Multiple sub-
sets of ILC3s are activated after intestinal tissue damage, and in the absence of ILC3s, 
epithelial activation is lost, correlating with increased pathology and severe damage to 
the intestinal crypts. Using ILC3-deficient Lgr5 reporter mice, we show that maintenance 
of intestinal stem cells after damage is severely impaired in the absence of ILC3s or the 
ILC3 signature cytokine IL-22. These data unveil a novel function of ILC3s in limiting 
tissue damage by preserving tissue-specific stem cells.
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to its role in differentiated epithelial cells, Stat3 activation is 
also an important pathway for survival of intestinal epithelial 
stem cells (Matthews et al., 2011).
Type 3 innate lymphoid cells (ILC3s) are innate immune 
cells that reside in the lamina propria of both the small and 
large intestines and are involved in tissue homeostasis, early 
defense against enteric pathogens, and containment of micro-
biota (Spits and Cupedo, 2012; Artis and Spits, 2015). In the 
intestines, multiple ILC3 subsets exist, two of which can be 
distinguished by mutual exclusive expression of the natural 
cytotoxicity receptor NKp46 and the chemokine receptor 
CCR6 (Sawa et al., 2010; Reynders et al., 2011). Most 
Nkp46+ ILC3s are found dispersed throughout the lamina 
propria, a localization that depends on the expression of CXCR6 
(Satoh-Takayama et al., 2014). In contrast, the majority of 
CCR6+ ILC3s are located in close proximity to the intestinal 
crypts in anatomically defined sites known as cryptopatches 
(Kanamori et al., 1996). Recent findings indicated that under 
inflammatory conditions, such as experimental graft-versus-
host disease, ILC3s can interact with the epithelial stem cells 
in the crypts, protecting them from T cell–mediated killing 
(Hanash et al., 2012).
The well-known ability of ILC3s to condition the local 
microenvironment, the close proximity of ILC3s to intestinal 
crypts, and the ability of ILC3s to communicate with epithe-
lial stem cells led us to hypothesize that ILC3s are involved 
in directing intestinal epithelial responses to tissue damage. 
Using the methotrexate (MTX) model of small intestinal 
damage, we now show that ILC3s are activated immediately 
after MTX administration, leading to a rapid activation of 
epithelial Stat3 and maintenance of ISCs. Our data reveal a 
novel function for ILC3s as organizers of the intestinal epi-
thelial response to tissue damage through activation of epi-
thelial cells and maintenance of ISCs and suggest that ILC3s 
might in future be therapeutically harnessed to prevent stem 
cell loss during chemotherapy.
RESULTS AND DISCUSSION
Damage-induced epithelial responses depend on Thy1+ cells
To study tissue damage responses in the small intestine, where 
most ILC3s reside, we exposed mice to MTX, an antimetab-
olite that inhibits folic acid metabolism and targets cells in 
S phase (Visentin et al., 2012). MTX application is a well-
established, self-resolving model of small intestinal damage 
ideally suited to dissect epithelial responses to sterile insult 
(Verburg et al., 2002; de Koning et al., 2006; Frank et al., 
2015). Upon MTX administration, mice lost weight until 
day 4, after which they fully recovered by day 7 (Fig. 1 A). 
This rapid weight loss correlated with intestinal pathology, 
which peaked as early as day 1 after the last MTX injection 
and subsequently stabilized at day 4 (Fig. 1 B) before recover-
ing by day 7 (not depicted). Pathological examination of the 
small intestine showed villus flattening and crypt hyperplasia 
with an overall loss of epithelial architecture (Fig. 1 C).
To visualize damage responses by epithelial cells, we assessed 
the number of cycling crypt cells, a measure of regenerative 
cells have been described, the best-characterized populations 
are the Lgr5-expressing cells that reside at the crypt bottom, 
interspersed with Paneth cells. These stem cells have the abil-
ity to give rise to all IECs ex vivo (Sato et al., 2009). Similar 
Figure 1. Epithelial responses to MTX. (A) Weight curve of WT 
mice treated with MTX. (B) MTX-induced pathology as described in 
Materials and methods. (C and D) Representative H&E staining (C) and 
immunostaining of Ki67 (D) in ileal sections at the indicated time 
points. (E) Number of KI67+ cells per crypt at the indicated time 
points. (F) Transcript analysis of Wnt5a in ileal tissues. (G) Representa-
tive immunostaining of pStat3 in ileal sections at the indicated time 
points. (A–C and G) Two to four independent experiments, n > 5 per 
time point. (D–F) Two independent experiments, n = 2–3 per time 
point. Mean ± SEM. **, P < 0.01. Bars, 50 µm.
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with isotype control antibodies showed normal restoration of 
the proliferative crypt compartment at day 4 (Fig. 2, A and B) 
and normal phosphorylation of Stat3 at day 1 after MTX 
(Fig. 2 C), confirming that adaptive immune cells are dispens-
able for these epithelial responses. In contrast, depletion of 
Thy1+ cells in Rag1/ mice strongly reduced the recovery 
of cycling cells at day 4 (Fig. 2, A and B) and impaired Stat3 
phosphorylation in IECs in response to tissue damage (Fig. 2 C). 
To validate the reduced Stat3 phosphorylation, we quantified 
the intensity of pStat3 staining on tissue sections using semi-
automated analysis and found a significant reduction in pStat3 
intensity at day 1 after the last MTX administration (Fig. 2 D). 
In addition, transcript analysis of total ileum revealed a reduc-
tion in levels of the Stat3 target gene Socs3, indicative of 
reduced Stat3 signaling (Fig. 2 E). Of note, pStat3-positive 
hematopoietic cells were found in the lamina propria of both 
control Rag1/ and Thy1-depleted Rag1/ mice (Fig. 2 C), 
suggesting differential regulation of Stat3 activation in epithe-
lial and hematopoietic cells. In conclusion, these experiments 
establish that restoration of the proliferating crypt cell com-
partment and epithelial phosphorylation of Stat3 after tissue 
capacity. Ki67+ crypt cells were reduced at day 1 but returned 
to baseline levels by day 4 (Fig. 1, D and E). Conversely, tran-
scripts for the regeneration-associated Wnt family member 
Wnt5a (Miyoshi et al., 2012) were increased early after dam-
age (Fig. 1 F). Phosphorylation of Stat3 in IECs plays a central 
role in mucosal wound healing (Ernst et al., 2014). Stat3 
phosphorylation was induced early after MTX application, 
peaking at day 1 (Fig. 1 G). 4 d after the last MTX injection, 
the phosphorylation of Stat3 had returned to baseline (Fig. 1 G). 
These data show that MTX-induced small intestinal dam-
age induces rapid and transient epithelial activation followed 
by regeneration.
Immediate MTX-induced pathology has been mainly 
attributed to direct effects on IECs, leading to epithelial cell–
intrinsic responses to tissue damage (Verburg et al., 2002). To 
determine whether the restoration of cycling crypt cells and 
the phosphorylation of Stat3 are indeed epithelial cell intrin-
sic or whether immune cells are involved, we administered 
MTX to Rag1/ mice that lack adaptive immunity and to 
Rag1/ mice pretreated with Thy1-depleting antibodies to 
eradicate innate immune cell subsets. Rag1/ mice treated 
Figure 2. Epithelial responses to tissue damage depend on Thy1+ cells. (A and B) Representative immunostaining of Ki67 in isotype- and -Thy1–
treated Rag1/ mice (A) and number of Ki67+ cells per crypt at the indicated time points (B). (C) Immunostaining of pStat3 in isotype- and -Thy1–
treated Rag1/ mice. (D) pStat3 intensity in ileal sections at the indicated time points. (E) Socs3 transcript levels relative to Gapdh from ileum at day 1 
after MTX (two independent experiments, n = 2–5 per time point). Mean ± SEM. *, P < 0.05; **, P < 0.01. Bars, 50 µm.
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pathology was similar in Rag1/ mice treated with either 
neutralizing IFN antibodies or isotype controls, suggesting 
that IFN is not critical for pathology in this model (Fig. 3 C). 
In line with the activation of ILC3s at the cytokine level, we 
also noted that expression of NKp46 was increased on ILC3s 
at day 1 after insult. This increased expression was apparent 
both at the protein (Fig. 3 D) and transcript level (Fig. 3 E). 
We next exposed Ncr1/ and littermate controls to MTX 
to determine whether absence of Nkp46 influences MTX-
induced pathology. However, the overall pathology in Ncr1/ 
mice did not differ from the Ncr1+/ littermate controls, ar-
guing against an essential role of NKp46 in response to MTX 
(Fig. 3 F). To confirm the transcription of the ILC3 activa-
tion–associated cytokines in an in vivo setting, we analyzed 
the intestines of Rag1/ mice in the presence or absence of 
Thy1+ cells. Transcript analysis of total ileum or protein analy-
sis after overnight ileal explant cultures clearly showed that 
the presence of Thy1+ cells was essential for generation of 
transcripts for Csf2, Tnf, Il22, Ltb, and Ifng (Fig. 3 G), as well 
as protein for both IL-22 and GM-CSF (Fig. 3 H) in response 
to tissue damage. These experiments unveil the rapid activa-
tion of ILC3 subsets in response to intestinal tissue damage.
damage are not epithelial cell–intrinsic responses but require 
the presence of Thy1+ cells.
ILC3s are activated in response to intestinal tissue damage
The finding that phosphorylation of epithelial Stat3 depends 
on Thy1+ cells led us to hypothesize that Thy1+ ILC3s 
are involved in the intestinal response to MTX-induced tissue 
damage. To determine whether ILC3s are activated in response 
to intestinal damage, CCR6+ and NKp46+ lamina propria 
ILC3s were analyzed for expression of activation-associated 
transcripts at 1 d after the last MTX injection (Fig. 3 A and B). 
Compared with homeostasis, CCR6+ ILC3s maintained 
transcription of Ltb, Rorc, Ifng, Il22, and Csf2 but showed in-
creased transcription of Tnf and Il17a (Fig. 3 A). NKp46+ 
ILC3s significantly increased transcription of Ltb, Rorc, Il22, 
Ifng, Csf2, and Tnf (Fig. 3 B). These data show that in response 
to intestinal tissue damage, both NKp46+ and CCR6+ ILC3s 
are activated, albeit in a differential manner. IFN-secreting 
ILC3s have been implicated in intestinal pathology (Klose et al., 
2013), and we therefore assessed the contribution of this ILC3-
derived cytokine to MTX-induced damage by neutralizing 
IFN in Rag1/ mice. After exposure to MTX, intestinal 
Figure 3. ILC3s are activated upon MTX-
induced damage. (A and B) Fold induction of 
the indicated transcripts relative to steady 
state of lamina propria CCR6+NKp46 ILC3s 
(A) and CCR6NKp46+ ILC3s (B) at day 1 after 
MTX. (C) Pathology score at day 4 after MTX 
of intestines of Rag1/ mice treated with 
neutralizing IFN or isotype control antibod-
ies. (D) Representative flow cytometry plot of 
NKp46 and CCR6 expression on lamina pro-
pria ILC3s at steady state and day 1 after MTX. 
(E) Transcript levels of Ncr1 relative to Gapdh 
from sorted CCR6NKp46+ ILC3s. (F) Pathol-
ogy score at day 4 after MTX of intestines of 
Ncr1+/ or Ncr1/ mice. (G) Transcriptional 
analyses of the indicated genes relative to 
Gapdh from ileum of isotype control or Thy1–
depleted Rag1/ mice at day 1 after MTX. 
(H) Protein levels of IL-22 and GM-CSF after 
overnight ileal explant cultures isolated at day 
1 after MTX. (A, B, D, and E) Four to six inde-
pendent experiments, n = 5–7 per time point. 
(C and F) Two independent experiments,  
n = 2–4 per group. (G and H) Two independent 
experiments, n = 2–3 per group. Mean ± SEM. 
*, P < 0.05; **, P < 0.01. ND, not detected.
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Figure 4. Absence of Rort augments crypt damage after MTX. (A) Ki67 in ileum sections of Rort/ mice at the indicated time points. (B) Num-
ber of Ki67+ cells in crypts of Rort/ mice at the indicated time points. (C) pStat3 in ileum sections from WT and Rort/ mice at the indicated time 
points. (D) Socs3 transcripts relative to Gapdh from ileum of WT and Rort/ mice at day 1 after MTX. (E) Wnt5a transcripts from ileum of Rort/ 
mice at the indicated time points. (F) Representative H&E staining of ileal sections at the indicated time points. (G) MTX-induced small intestinal damage 
in WT and Rort/ mice as specified in Materials and methods. (H) Representative high-power magnification of ileal crypts of WT and Rort/ mice 4 d 
after MTX. (I) Crypt damage in WT and Rort/ mice at days 1 and 4. (J) Ratio between bax and bcl2l1 transcript levels in ileum of WT and Rort/ mice 
at day 1 after MTX. (A and B) Two independent experiments, n = 3–4 per group. (C, D, and F–I) Two to four independent experiments, n = 2–5 per group. 
(E and J) Two independent experiments, n = 2–3 per group. Mean ± SEM. *, P < 0.05; **, P < 0.01. Bars: 50 µm (A, C, and F); 10 µm (H).
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ILC3 deficiency aggravates MTX-induced damage
Depletion of Thy1+ cells diminished regeneration of crypt 
cells and activation of epithelial Stat3 in response to MTX, 
and ILC3s were activated early after tissue damage. How-
ever, because Thy1 antibodies do not specifically target 
ILC3s, we next exposed ILC3-deficient Rort/ mice to 
MTX to confirm that ILC3s are responsible for the observed 
damage-associated epithelial responses. Rort/ mice showed 
impaired recovery of the cycling crypt compartment at 
day 4 after MTX (Fig. 4, A and B), and IECs in Rort/ 
mice did not show phosphorylation of Stat3 in response 
to tissue damage (Fig. 4 C). Consequently, Stat3 signaling 
was reduced as indicated by lower levels of Socs3 transcripts 
(Fig. 4 D). In contrast, induction of Wnt5a transcription was 
independent of ILC3s and occurred normally in Rort/ 
mice (Fig. 4 E).
Histological analysis of the small intestines of MTX- 
exposed Rort/ mice revealed a slight increase in overall 
pathology at day 4 after MTX (Fig. 4 F). The differences in 
overall pathology between WT and Rort/ mice did not 
reach statistical significance, even though there seemed to 
be a trend toward increased pathology in Rort/ mice at 
day 4 (Fig. 4 G).
To understand this trend, we performed differential pa-
thology scoring on intestinal villus and crypt compartments. 
This revealed a significant increase in the damage sustained 
by the small intestinal crypts in Rort/ mice compared 
with control mice (Fig. 4 H). The extent of crypt epithelial 
flattening, the presence of crypt abscesses, and the eventual 
loss of crypts were all significantly increased in the absence of 
Rort (Fig. 4 I). Survival of epithelial cells in response to tis-
sue damage is regulated by the balance between several pro- 
and antiapoptotic molecules (Vereecke et al., 2011). To assess 
whether this balance was shifted in the absence of Rort, we 
determined transcript levels of the proapoptotic gene Bax and 
the antiapoptotic gene Bcl2l1 (BclXL) in ileum (Fig. 3 G). In 
Rort/ mice, 1 d after MTX, the Bax/Bcl2l1 ratio was sig-
nificantly increased, indicating a shift toward a more proapop-
totic program in the absence of ILC3s. Combined, these data 
suggest that the absence of Rort+ ILC3s augments tissue 
damage to the stem cell–containing intestinal crypts in re-
sponse to MTX.
ILC3s preserve ISCs after tissue damage
A prerequisite for epithelial regeneration is the presence of 
crypt-residing ISCs (Potten, 1990). Because Rort/ mice 
exposed to MTX had increased crypt pathology and reduced 
crypt proliferation, we investigated the fate of Lgr5+ ISCs in 
response to MTX. To determine whether Lgr5+ ISCs are sen-
sitive to MTX, we exposed Lgr5-GFP reporter mice to MTX 
and assessed the percentage of GFP+ cells in purified crypts 
of duodenum, jejunum, and ileum at several time points 
after treatment (Fig. 5 A). Lgr5+ ISC numbers declined di-
rectly after treatment, indicating that ISCs were targeted by 
MTX. Stem cell recovery started after day 4 and numbers 
normalized by day 6 (Fig. 5 A). To investigate the role of 
Rort-expressing ILC3s in epithelial stem cell maintenance, 
we generated radiation bone marrow chimeras by transferring 
either WT or Rort-deficient bone marrow into lethally ir-
radiated Lgr5-GFP recipient mice. To eliminate host-derived 
radioresistant ILC3s, both groups were treated with depleting 
-Thy1 antibodies. Such Rort/-Lgr5-GFP chimeric mice 
provide a model to study GFP-labeled Lgr5+ ISCs in the ab-
sence of Rort+ hematopoietic cells. In response to MTX, 
Rort/-Lgr5-GFP chimeric mice developed increased in-
testinal pathology compared with WT chimeric mice (Fig. 5, 
B and C), as characterized by crypt epithelial flattening, crypt 
abscesses, and crypt loss (Fig. 5 D), resembling the pathology 
in Rort-deficient mice. To determine the effect of absence 
of Rort+ lymphocytes on ISCs, we purified small intestinal 
crypts from Rort-sufficient and -deficient chimeric mice. 
At steady state, the percentages of Lgr5-GFP+ cells did not 
significantly differ between both groups (Fig. 5 E). At day 4 
after MTX, flow cytometric analyses revealed a significant 
reduction in the percentage of Lgr5-GFP+ ISCs within the 
EpCAM-1+ crypt epithelial cell fraction (Fig. 5 F). This re-
duction in Lgr5+ ISCs occurred along the entire length of 
the small intestine. In duodenum, jejunum, and ileum Lgr5+ 
ISCs were reduced by 68% (68.3 ± 3.1%), 71% (71.2 ± 1.4%), 
and 52% (52.1 ± 8.1%), respectively (Fig. 5 G), highlight-
ing the importance of Rort+ ILC3s as guardians of ISCs 
after damage.
IL-22 is an ILC3 signature cytokine involved in commu-
nication between ILC3s and crypt epithelial cells (Hanash et al., 
2012) and is transcribed after MTX-induced damage. To de-
termine whether IL-22 mechanistically links ILC3s to stem 
cell maintenance after damage, we used antibodies to neutral-
ize this cytokine during MTX treatment. IL-22 blockade led 
to a significant loss of stem cell maintenance in the duode-
num, whereas ISC numbers in jejunum and ileum were less 
affected (Fig. 5, H and I). These data indicate that IL-22 is 
one of the factors involved in stem cell maintenance after 
tissue damage.
Collectively, our findings reveal that ILC3s preserve organ-
specific stem cells in response to tissue insult. MTX applica-
tion evokes a rapid and transient activation of epithelial Stat3, 
followed by epithelial regeneration in a Thy1+Rort+ cell–
dependent manner. Multiple subsets of ILC3s respond to intes-
tinal tissue damage, and absence of ILC3s aggravates pathology 
in intestinal crypts. Importantly, we could show that the main-
tenance of ISCs after cytotoxic therapy is regulated by ILC3s 
and that, mechanistically, IL-22 is one of the effector molecules 
involved. Our findings thus highlight a previously unappreci-
ated feature of ILC3s in coordinating epithelial responses to 
tissue damage in the small intestine. Their location in close 
proximity to the crypts and their resistance to chemo- and 
radiotherapy-induced cell death put ILC3s in the ideal position 
to minimize tissue damage after cytotoxic insult, and control-
ling ILC3 responses might hold the key to designing future 
therapeutic strategies aimed at minimizing intestinal damage 
in patients undergoing anticancer therapies.
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Monoclonal antibodies. Monoclonal antibodies used were EpCAM-1 
(G8.8; BioLegend); CD45 (30F11; Invitrogen); Lin-biotin (eBioscience); 
CD19 (1D3), CD3 (145-2C11), CD11c (N418), CD11b (M1/70), Gr1 
(RB6-8C5), and Streptavidin (BioLegend); NK1.1 (PK136; eBioscience); 
CD127 (A7R34; eBioscience); CD117 (2B8; BD); NKp46 (2941.4; eBioscience); 
and CCR6 (29-2L17; BioLegend).
MTX. 8–12-wk-old mice were injected i.p. with 120 mg/kg MTX (PCH) 
at day 1 and with 60 mg/kg at day 0. Body weight was monitored daily, 
and tissues were collected at days 1 and 4 after the last MTX injection.
Cytokine neutralization. 150 µg anti–IL-22 antibody (8E11; gift from 
W. Ouyang, Genentech, South San Francisco, CA) or mouse IgG1 isotype 
MATERIALS AND METHODS
Mice. C57BL/6, Rort/, Rag1/, Ncr1/ (a gift from O. Mandel-
boim, Hebrew University of Jerusalem, Jerusalem, Israel; Gazit et al., 2006), 
and Lgr5-eGFP mice were bred in the animal facility of the Erasmus Uni-
versity Medical Center Rotterdam. Animal experiments were approved by 
the Animal Ethics Committee of the ErasmusMC and performed in accor-
dance with institutional guidelines. Age- and gender-matched littermates 
were used whenever possible.
Thy1+ cells were depleted using -Thy1 antibodies (clone YTS154; 
provided by H. Waldmann, University of Cambridge, Cambridge, England, 
UK) or isotype controls (a-phytochrome AFRC MAC5.1). Antibodies 
were diluted in saline and mice were injected i.p. with 200 µg every other 
day for 2 wk.
Figure 5. ILC3s preserve ISCs after MTX-induced damage. (A) Percentage of GFP+ stem cells within EpCAM1+ cells from purified intestinal crypts at 
the indicated time points. (B) Representative H&E staining of ileal sections of WT and Rort/ chimeras at day 4 after MTX. (C) Small intestinal damage 
in WT (black bars) and Rort/ (gray bars) chimeras at day 4 after MTX as described in Materials and methods. (D) Crypt pathology score. (E) Frequency 
of GFP+ cells from WT and Rort/ chimeras at homeostasis. (F) Representative plots of purified crypts of WT and Rort/ chimeras at day 4 after MTX. 
Numbers adjacent to outlined areas indicate percentage of EpCAM+Lgr5-GFP+ cells. (G) Frequency of GFP+ cells from WT and Rort/ chimeras at day 4 
after MTX. (H) Representative plots of purified duodenal crypts at day 4 after MTX of Lgr5-GFP mice treated with aIL-22 or control antibodies. (I) Fre-
quency of GFP+ cells at day 4 after MTX from Lgr5-GFP mice treated with aIL-22 or control antibodies. (A) Two independent experiments, n = 2 per group. 
(B–D, F, and G) Two independent experiments with two to four mice per group. (E) Two independent experiments, WT: n = 1 per group, KO: n = 1–3 per 
group. (H and I) Two independent experiments with two to five mice per group. Mean ± SEM. *, P < 0.05. Bar, 50 µm.
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times for 1 h. Supernatants were passed through a 70-µm cell strainer and 
washed in cold HBSS. Pellets were suspended in 90% Percoll, overlaid 
with 40% Percoll, and centrifuged at 1,800 rpm for 20 min to allow sepa-
ration of mononuclear cells by density gradient. Interphase was washed 
and stained with conjugated antibodies. Lamina propria lymphocytes were 
analyzed by flow cytometry (FACSAria III; BD), and ILC3s were sorted as 
CD45+LinNK1.1CD127+CD117+CCR6+/NKp46+/ (see Fig. S1 for 
full gating strategy).
Transcript analysis. RNA was extracted using the NucleoSpin RNA XS 
kit (MACHERY-NAGEL). RNA from sorted cells was amplified according 
to the manufacturer’s protocol (Ovation PicoSL WTA System V2; NuGen). 
For quantitative PCR (qPCR), a Neviti Thermal Cycler (Applied Biosys-
tems) and DyNAmo Flash SYBR Green qPCR kit (Finnzymes) were used, 
with the addition of MgCl2 to a final concentration of 4 mM. All reactions 
were performed in duplicate and are normalized to the expression of Gapdh. 
Relative expression was calculated by the cycling threshold (CT) method as 
2CT. The primer sequences can be found in Table S1.
Statistical analysis. Samples were analyzed using unpaired Mann–Whitney 
test. P-values <0.05 were considered significant. Data are shown as 
mean ± SEM.
Online supplemental information. Fig. S1 shows the gating strategy for 
lamina propria ILC3s. Table S1 lists the primer sequences used for qPCR. 
Online supplemental material is available at http://www.jem.org/cgi/ 
content/full/jem.20150318/DC1.
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